Autism is a complicated condition with many degrees of severity, and can overlap with other related disorders. The US Centers for Disease Control and Prevention revealed that the prevalence of autism in the United States was just one in 5,000 in 1975. However, this figure has leapt to one in 150 in 2002, and reached one in 68 in 2012. Researchers at Penn State University suggest that the way autism is diagnosed in the United States has led to an apparent tripling in cases in recent years that does not reflect reality.
The study said, "Rather, more youths with intellectual or developmental disabilities are being reclassified as autistic. This new research provides the first direct evidence that much of the increase may be attributable merely to a reclassification of individuals with related neurological disorders rather than to an actual increase in the rate of new cases of autism."
AdvertisementScientists analyzed 11 years of special-education enrollment data on an average of 6.2 million children per year. They found no overall increase in the number of students enrolled in special education. The research team also found that the increase in students diagnosed with autism was offset by a nearly equal decrease in students diagnosed with other intellectual disabilities that often co-occur with autism. Therefore, what may appear to be an epidemic of autism is more likely the result of shifting patterns of autism diagnosis over the years.
Lead researcher Santhosh Girirajan, assistant professor of biochemistry and molecular biology and of anthropology at Penn State, said, "The high rate of co-occurrence of other intellectual disabilities with autism, which leads to diagnostic reclassification, is likely due to shared genetic factors in many neurodevelopmental disorders. Every patient is different and must be treated as such. Standardized diagnostic measures incorporating detailed genetic analysis and periodic follow up should be taken into account in future studies of autism prevalence."
The study appeared in the American Journal of Medical Genetics.
P Glenmark India Launches Teneligliptin for Management of Type 2 Diabetes Chemically Modified Nucleotides Could Be Used for Specific Killing of Cancer Cells M
You May Also Like